Stock listing

Frankfurt:0IT Satellos Bioscience Inc Aktie

German listing (Frankfurt) of Satellos Bioscience Inc · home listing TSX:MSCL

Follow Satellos Bioscience Inc into a list and get an email when it puts out news.

Home listing price · TSX:MSCL

$8.24 CAD -0.38 (-4.4%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, TSX:MSCL

Past year -4.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$8.11 – $8.50 CADNov 20, 2026
Volume
13,796 sharesNov 20, 2026
Market cap
$174.8M CADAt the close on Nov 20, 2026 · price × 21.22M shares outstanding
52-week range
$7.56 – $18.98 CADLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$139,697 CADMedian day 10,700 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Satellos Bioscience Inc logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
TSX:MSCL · Home$8.24 CAD-0.38 (-4.4%)13,796$8.50$8.50$8.11$8.62Close on Nov 20, 2026
NASDAQ:MSLE$5.68 USD-0.12 (-2.1%)113,907$5.71$6.001$5.62$5.80Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · TSX:MSCL · CAD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$8.24-0.38-4.4%$8.50$8.50$8.1113,796
$8.62-0.28-3.1%$8.97$9.20$8.5512,252
$8.90-0.29-3.2%$9.05$9.10$8.7528,972
$9.19-0.31-3.3%$9.33$9.44$9.0817,664
$9.50-0.07-0.7%$10.24$10.24$9.286,491
$9.57-0.04-0.4%$9.75$9.75$9.2523,176
$9.61-0.34-3.4%$9.88$10.00$9.615,762
$9.95-0.49-4.7%$10.47$10.50$9.8915,506
$10.44+0.32+3.2%$10.15$10.51$9.9912,328
$10.12+1.10+12.2%$9.40$10.49$9.2029,021
$9.02-0.29-3.1%$9.08$9.08$8.6534,191
$9.31+0.31+3.4%$9.00$9.31$9.00401
$9.00-0.05-0.6%$9.08$9.11$9.007,819
$9.05-0.49-5.1%$9.32$9.32$9.05826
$9.54-0.06-0.6%$9.60$9.60$9.053,137
$9.60+0.57+6.3%$9.08$9.76$9.053,019
$9.03-0.64-6.6%$9.67$9.88$9.0113,760
$9.67+0.34+3.6%$9.52$10.00$9.529,036
$9.33+0.20+2.2%$9.25$9.33$9.0011,145
$9.13+0.01+0.1%$9.23$9.38$9.057,208
$9.12-0.40-4.2%$9.39$9.68$9.1217,700
$9.52-0.19-2.0%$9.84$9.84$9.404,900
$9.71+0.53+5.8%$9.37$9.71$9.279,300
$9.18-0.07-0.8%$9.60$9.65$9.025,700
$9.25-0.54-5.5%$10.00$10.00$9.2513,200
$9.79+0.29+3.1%$9.61$9.79$9.404,000
$9.50-0.40-4.0%$10.01$10.01$9.486,100
$9.90-0.81-7.6%$10.70$10.70$9.9037,700
$10.71+0.29+2.8%$10.50$11.10$10.3412,200
$10.42-0.71-6.4%$11.64$11.64$10.3119,400
$11.13+0.36+3.3%$10.75$11.83$10.5610,100
$10.77-0.73-6.3%$11.74$11.75$10.7213,200
$11.50-0.51-4.2%$12.47$12.47$11.509,400
$12.01-0.08-0.7%$12.41$12.41$12.0125,500
$12.090.000.0%$12.02$12.50$12.024,400
$12.09-0.11-0.9%$12.49$12.49$12.0210,400
$12.20-0.26-2.1%$12.29$12.42$12.0214,500
$12.46-0.04-0.3%$12.35$12.64$12.353,000
$12.50+0.16+1.3%$12.20$12.51$12.171,700
$12.34+0.17+1.4%$12.75$12.75$11.979,600
$12.17-0.51-4.0%$12.50$12.50$12.0117,500
$12.68-0.19-1.5%$12.87$12.87$12.455,700
$12.87-0.16-1.2%$13.10$13.10$12.8712,400
$13.03-0.24-1.8%$13.48$13.49$13.034,800
$13.27+0.27+2.1%$13.34$13.50$13.2713,600
$13.00-0.01-0.1%$13.03$13.36$13.0010,900
$13.01-0.50-3.7%$13.13$13.15$13.015,900
$13.51+0.31+2.3%$14.00$14.00$13.516,100
$13.20-0.73-5.2%$13.99$14.16$13.207,100
$13.93+0.08+0.6%$13.95$14.34$13.5610,500
$13.85+1.08+8.5%$12.94$14.25$12.8922,500
$12.77+0.32+2.6%$12.45$13.26$12.4431,100
$12.45-0.08-0.6%$12.35$12.62$12.351,100
$12.53-0.07-0.6%$12.57$12.79$12.3911,500
$12.60-0.25-1.9%$12.41$12.66$12.418,600
$12.85-0.16-1.2%$13.03$13.03$12.514,200
$13.01+0.90+7.4%$12.95$13.01$12.1429,600
$12.11-0.97-7.4%$13.21$13.22$12.119,300
$13.080.000.0%$13.00$13.10$12.979,800
$13.08+0.08+0.6%$13.00$13.21$13.0019,000
$13.00-0.29-2.2%$13.29$13.68$13.0012,700
$13.29-0.22-1.6%$13.52$13.52$13.0018,700
$13.51-0.30-2.2%$13.70$13.81$13.4017,900
$13.81-0.01-0.1%$14.00$14.00$13.4521,000

Splits

2 splits since 2021 · TSX:MSCL · every price before a split is adjusted for it

DayRatioWhat
1-for-12Consolidation
1-for-20Consolidation
Ticker
Frankfurt:0IT
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Latest news

All Satellos Bioscience Inc news

Satellos Bioscience Inc on 6ix

Sector
Health care
Industry
Biotechnology
News releases
31 in the last 12 months · 122 in all · newest Nov 12, 2026 · oldest 2021
Decks
17 decks · latest Nov 6, 2026

Where Satellos Bioscience Inc is listed

ListingExchangeCountryCurrency
TSX:MSCL · Home listingTSXCanadaCAD
NASDAQ:MSLENASDAQUnited StatesUSD
Cboe Canada:MSCLCboe CanadaCanadaCAD
LS Exchange:A4211WLS ExchangeGermanyEUR
Lang & Schwarz:A4211WLang & SchwarzGermanyEUR
BOATS:MSLEBOATSUnited StatesUSD
Frankfurt:0IT · This pageFrankfurtGermanyEUR
Stuttgart:0ITStuttgartGermanyEUR
Tradegate:0ITTradegateGermanyEUR

Valuation

Price/book 2.5× against a median of 1.7×: 7th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$99.28M CAD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
2.5×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P/TSX Composite
0.49

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Satellos Bioscience Inc · TSX:MSCLUS$121.9MUS$69.23Mn/an/an/a2.5×n/a0.0×0.49
MacroGenics, Inc. · NASDAQ:MGNXUS$125.3M−US$127.6Mn/a−0.9×n/a5.0×−34.6%1.4×0.83
PolyPid Ltd. · NASDAQ:PYPDUS$124.3MUS$119.3Mn/an/an/a23.1×n/a0.3×0.93
Compass Therapeutics, Inc. · NASDAQ:CMPXUS$123.9M−US$29.89Mn/an/an/a0.9×n/a0.1×1.22
Humacyte, Inc. · NASDAQ:HUMAUS$123.7MUS$96.01Mn/a40.1×n/a6.8×n/a2.0×2.56
Biomm SA · BMFBOVESPA:BIOM3US$122.6MUS$136.5M18.4×2.1×12.3×2.2×10.3%0.3×n/a
Invivyd, Inc. · NASDAQ:IVVDUS$122.0MUS$3.86Mn/a0.1×n/a0.8×−214.8%0.1×2.06
Alar Pharmaceuticals Inc · TPEX:6785US$121.0MUS$51.66Mn/a568×n/a1.7×n/a0.0×n/a
CANbridge Pharmaceuticals Inc. · HKEX:1228US$120.4MUS$111.5Mn/a13.3×n/an/a−146.4%n/an/a
Atrium Therapeutics, Inc. · NASDAQ:RNAUS$118.4M−US$113.0Mn/a−2.9×n/a0.6×−229.7%0.0×0.76
Adagene, Inc. · NASDAQ:ADAGUS$118.2M−US$3.65Mn/a−0.5×n/a1.1×−229.6%0.1×1.43
Median of the othersUS$122.3MUS$27.76M18.4×1.1×12.3×1.7×−180.6%0.1×1.22

Forecasts

Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
17.67 CAD · Analysts' mean
EPS, year to Dec 2026
-3.11 · 4 analysts

Team and board

Officers

OfficerRole
Frank GleesonCo-founder, Chief Executive Officer, Board Director
Liz WilliamsCFO
Caitlin LowieVice President, Investor Relations & Communications
Antoinette PaoneChief Development Officer and Head of Regulatory Affairs

Board

DirectorRole
Geoff MacKayChair, BOD | Chair, Compensation Committee
Adam MostafaDirector | Chair, Audit Committee
Brian BloomDirector
Frank GleesonCo-founder, Chief Executive Officer, Board Director
Franklin M. BergerDirector
Iris Loew-FriedrichDirector
Mark NawackiDirector
Selwyn HoDirector
Stephanie BrownDirector | Chair, Nominations and Governance Committee

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · Before open−0.4%
Q2 2026Aug 13, 2026 · After close−3.4%
Q1 2026May 13, 2026 · Before open−2.2%
Q4 2025Mar 27, 2026 · Before open−10.3%
Q3 2025Nov 14, 2025 · Before open+5.8%
Q2 2025Aug 13, 2025 · Before open−8.3%
Q1 2025May 13, 2025 · Before open+4.7%
Q4 2024Mar 26, 2025+2.6%
Q3 2024Nov 13, 2024 · Before open+1.2%
Q2 2024Aug 12, 2024 · After close+4.3%
All 14 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · After close0.0%
Q4 2023Mar 27, 2024 · Before open+4.3%
Q3 2023Nov 22, 2023 · After close0.0%
Q4 2022Mar 29, 2023 · After close+24.4%

Open Events

Decks

DeckKindSlidesDate
Corporate Update (November 2026)Corporate update17 slidesNov 6, 2026
Corporate Update (July 2026)Corporate update14 slidesJul 8, 2026
2026 Bloom Burton & Co. Healthcare Investor ConferenceConference23 slidesApril 2026
Technical Presentation (February 2026)Technical52 slidesFeb 24, 2026
Investor Presentation (February 2026)Investor deck21 slidesFebruary 2026
Investor Presentation (October 2025)Investor deck19 slidesOctober 2025
Investor Presentation (June 2025)Investor deck22 slidesJun 5, 2025
CureDuchenne FUTURES National Conference 2025Conference11 slidesMay 24, 2025
2025 Bloom Burton & Co. Healthcare Investor ConferenceConference26 slidesMay 5, 2025
30th Annual PPMD Conference 2024Conference12 slidesJun 29, 2024
All 17 decks
DeckKindSlidesDate
Investor Presentation (February 2024)Investor deck17 slidesFebruary 2024
Investor Presentation (February 2023)Investor deck21 slidesFebruary 2023
Life Science Investor Forum 2022Conference17 slidesJun 23, 2022
Investor Day (March 2022)Investor day16 slidesMar 13, 2022
Investor Presentation (February 2022)Investor deck21 slidesFeb 22, 2022
Market Radius (February 2022)Conference19 slidesFeb 9, 2022
Investor Presentation (December 2021)Investor deck21 slidesDecember 2021

Open Decks

Financings

RaiseDateIn US dollars
Public offering of common shares and pre-funded warrants
Closed: US$57.2M raised · US$10.1 a share · Leerink Partners +4
Dealers: Leerink Partners (co-lead), Guggenheim Securities (co-lead), Oppenheimer & Co. (co-lead), Bloom Burton, Bloom Burton Securities Inc.
Buyers: Franklin Berger (24,750 common shares); Mark Nawacki (30,000 common shares)
Insiders: Director Franklin Berger purchased 24,750 common shares; no other insiders participated.
Use of proceeds: Research and development including SAT-3247 clinical trials, other discovery and pre-clinical programs, working capital and general corporate purposes
Feb 9, 2026
Warrant exercise of share purchase warrants
Closed: C$1.04M raised
Sep 22, 2025US$754,560

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue000025.0K
Cost of revenue5.09K7.00K3.73M165.7K4223.06K1.54K23.5K27.4K
Gross profit-5.09K-8.82M-3.73M-165.7K-422-3.06K-1.54K-23.5K-27.4K
Research and development18.4M14.4M8.82M2.59M1.88M892.8K917.5K1.42M786.6K564.2K
Selling, general and administrative7.44M6.06M4.66M1.13M182.4K857.4K
Operating income-26.5M-20.4M-15.5M-8.43M-6.65M-2.77M-2.21M-2.20M-1.47M-1.23M
Depreciation and amortization4.00K15.0K7.00K337.0K165.7K4227341.54K23.5K27.4K
EBITDA-26.5M-20.4M-15.5M-8.09M-6.48M-2.77M-2.20M-2.20M-1.45M-1.20M
Interest expense177.0K50.9K985.3K23.0K
Income before tax-24.7M-20.6M-15.9M-11.3M-15.5M-1.58M-2.20M-1.70M-1.24M-1.49M
Income tax172.0K177.0K5.00K-42.4K-270.6K-264.8K
Net income-24.9M-20.6M-15.9M-11.3M-15.5M-1.58M-1.94M-1.70M-1.24M-1.49M
Earnings per share, basic-1.70-2.16-2.21-3.81-7.73-0.58-0.71-4.84-3.51-4.23
Earnings per share, diluted-1.70-2.16

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents9.80M40.1M22.1M1.92M4.87M717.5K399.1K10.1K1.13M2.36M
Short-term investments17.9M8.47M17.5M2.36M
Receivables369.3K583.0K260.4K528.0K409.1K12.5K129.7K88.4K37.1K
Inventory-583.0K-260.0K-528.0K-409.1K
Current assets31.9M50.7M40.3M2.23M5.44M1.13M1.07M175.0K1.37M2.42M
Property, plant and equipment5.00K4.00K13.8K5.85K
Goodwill-190
Total assets31.9M50.7M44.3M6.20M12.6M1.13M1.07M178.1K1.37M2.45M
Accounts payable4.11M3.58M1.04M1.47M1.13M128.5K629.2K
Current liabilities4.11M3.58M3.62M2.83M2.10M220.0K664.8K802.5K288.2K138.1K
Total debt1.09M
Total liabilities4.11M3.58M3.62M2.83M2.10M1.31M664.8K802.5K288.2K138.1K
Shareholders' equity27.8M47.2M40.7M3.37M10.5M-183.8K408.6K-624.4K1.09M2.31M
Shares outstanding14.6M7.20M2.97M2.01M2.74M2.74M351.9K351.9K351.9K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2016
Cash from operations-23.6M-18.3M-14.4M-5.64M-5.03M-1.66M-1.92M-1.10M-1.33M
Capital spending-6.00K-4.00K-18.0K-3.00K-7.25K0-771-3.19K-4.03K
Free cash flow-23.6M-18.3M-14.5M-5.79M-5.04M-1.66M-1.93M-1.11M-1.34M
Cash from investing-9.42M4.66M-17.5M-3.00K1.74M-771-3.19K-4.03K
Cash from financing2.24M37.6M51.0M2.77M7.45M1.98M1.16M
Dividends paid00
Share buybacks2.24M37.0M2.02M
Change in cash-30.3M23.4M20.1M-2.95M4.15M318.4K-767.9K-1.12M-366.5K

Open Financials

Filings

FilingDateTypeFiled with
6-K · Report of a foreign issuerNov 12, 2026Current reportSEC
6-K · Report of a foreign issuerNov 6, 2026Current reportSEC
6-K · Report of a foreign issuerNov 5, 2026Current reportSEC
6-K · Report of a foreign issuerOct 27, 2026Current reportSEC
6-K · Report of a foreign issuerOct 21, 2026Current reportSEC
6-K · Report of a foreign issuerOct 5, 2026Current reportSEC
6-K · Report of a foreign issuerSep 30, 2026Current reportSEC
6-K · Report of a foreign issuerSep 24, 2026Current reportSEC
6-K · Report of a foreign issuerSep 15, 2026Current reportSEC
6-K · Report of a foreign issuerSep 9, 2026Current reportSEC
All 56 filings
FilingDateTypeFiled with
6-K · Report of a foreign issuerSep 1, 2026Current reportSEC
6-K · Report of a foreign issuerAug 14, 2026Current reportSEC
SUPPLAug 14, 2026Other filingsSEC
6-K · Report of a foreign issuerAug 13, 2026Current reportSEC
F-XAug 11, 2026Other filingsSEC
F-10 · Registration statementAug 11, 2026Offer documentSEC
6-K · Report of a foreign issuerJul 8, 2026Current reportSEC
6-K · Report of a foreign issuerJun 29, 2026Current reportSEC
6-K · Report of a foreign issuerJun 25, 2026Current reportSEC
6-K · Report of a foreign issuerJun 17, 2026Current reportSEC
6-K · Report of a foreign issuerJun 17, 2026Current reportSEC
6-K · Report of a foreign issuerMay 27, 2026Current reportSEC
6-K · Report of a foreign issuerMay 20, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerMay 15, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeMay 12, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerApr 9, 2026Current reportSEC
S-8 · Registration statement for employee plansMar 27, 2026Offer documentSEC
40-F · Annual reportMar 27, 2026Annual reportSEC
6-K · Report of a foreign issuerMar 27, 2026Current reportSEC
6-K · Report of a foreign issuerMar 10, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 24, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 19, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 18, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 17, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 12, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 10, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 9, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 6, 2026Current reportSEC
SUPPLFeb 6, 2026Other filingsSEC
CERT · Exchange's certificate of listingFeb 6, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeFeb 5, 2026Other filingsSEC
F-XFeb 5, 2026Other filingsSEC
F-10 · Registration statementFeb 5, 2026Offer documentSEC
DJan 3, 2025Other filingsSEC
DMay 25, 2023Other filingsSEC
DSep 27, 2022Other filingsSEC
DSep 10, 2019Other filingsSEC
DMar 8, 2019Other filingsSEC
DFeb 5, 2014Other filingsSEC
D/ANov 21, 2013Other filingsSEC
DNov 15, 2011Other filingsSEC
D/ADec 1, 2009Other filingsSEC
DNov 6, 2009Other filingsSEC
REGDEXMar 25, 2009Other filingsSEC
REGDEXDec 19, 2007Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Satellos Bioscience Inc’s releases · as of Feb 9, 2026

Common shares
21,216,439
Fully diluted
21,216,439

Fully diluted

LineShares
Common shares21,216,439

Share count over time

CountShares
Nov 22, 202621,216,439

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Franklin Templeton939K4.4%US$6.09MSep 30, 2026
Siren, L.L.C.892K4.2%US$7.58MSep 30, 2026
Vivo Capital, LLC814K3.8%US$6.92MSep 30, 2026
Point72 Asset Management, L.P.682K3.2%US$5.8MSep 30, 2026
Sphera Funds Management LTD.639K3.0%US$5.43MSep 30, 2026
Saturn V Capital Management LP517K2.4%US$4.39MSep 30, 2026
Woodline Partners LP500K2.4%US$4.25MSep 30, 2026
Montanova Capital, LLC475K2.2%US$4.04MSep 30, 2026
Stonepine Capital Management, LLC455K2.1%US$3.87MSep 30, 2026
683 Capital Management, LLC355K1.7%US$3.02MSep 30, 2026
All 30 holders
HolderSharesOf the companyValueAs of
Soleus Capital Management, L.P.330K1.6%US$2.81MSep 30, 2026
ADAR1 Capital Management, LLC257K1.2%US$2.18MSep 30, 2026
Millennium254K1.2%US$2.16MSep 30, 2026
AWM Investment Company, Inc.180K0.85%US$1.53MSep 30, 2026
Avidity Partners Management LP164K0.77%US$1.39MSep 30, 2026
Adage Capital Partners Gp, L.L.C.100K0.47%US$850KSep 30, 2026
Crcm LP68,0600.32%US$579KSep 30, 2026
Empery Asset Management, LP58,0000.27%US$493KSep 30, 2026
Citadel43,1900.20%US$367KSep 30, 2026
Quadrature Capital Ltd38,9160.18%US$331KSep 30, 2026
Jane Street21,4170.10%US$182KSep 30, 2026
RBC14,2900.07%US$121KSep 30, 2026
Geode Capital13,0210.06%US$111KSep 30, 2026
China Universal Asset Management Co., Ltd.12,8000.06%US$110KSep 30, 2026
Morgan Stanley11,8620.06%US$101KSep 30, 2026
BlackRock4,2100.02%US$35,786Sep 30, 2026
BNP Paribas1,056<0.01%US$8,976Sep 30, 2026
Provenance Wealth Advisors, LLC83<0.01%US$706Sep 30, 2026
Federation des caisses Desjardins du Quebec19<0.01%US$162Sep 30, 2026
Caitong International Asset Management Co., Ltd1<0.01%US$8Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Franklin Biotechnology Discovery Fund343K1.6%US$3.43MJul 31, 2026
Fidelity Nasdaq Composite Index Fund11,9070.06%US$86,921May 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Franklin Milan Berger
Director of Issuer
Buy100CAD 8.93CAD 893Jul 14, 2026
Franklin Milan Berger
Director of Issuer
Buy939CAD 9.03CAD 8,479Jul 14, 2026
Franklin Milan Berger
Director of Issuer
Buy100CAD 9.07CAD 907Jul 14, 2026
Franklin Milan Berger
Director of Issuer
Buy100CAD 9.09CAD 909Jul 14, 2026
Franklin Milan Berger
Director of Issuer
Buy2,575CAD 9.13CAD 23,510Jul 14, 2026
Franklin Milan Berger
Director of Issuer
Buy370CAD 8.98CAD 3,323Jul 14, 2026
Franklin Milan Berger
Director of Issuer
Buy400CAD 9.01CAD 3,604Jul 14, 2026
Franklin Milan Berger
Director of Issuer
Buy1,777CAD 9.04CAD 16,064Jul 14, 2026
Franklin Milan Berger
Director of Issuer
Buy100CAD 8.92CAD 892Jul 14, 2026
Franklin Milan Berger
Director of Issuer
Buy1,001CAD 8.91CAD 8,919Jul 13, 2026
All 24 trades
TradeTradeSharesPriceValueDate
Franklin Milan Berger
Director of Issuer
Buy400CAD 8.89CAD 3,556Jul 13, 2026
Franklin Milan Berger
Director of Issuer
Buy2,000CAD 9.09CAD 18,180Jul 13, 2026
Franklin Milan Berger
Director of Issuer
Buy1CAD 8.49CAD 8Jul 13, 2026
Franklin Milan Berger
Director of Issuer
Buy100CAD 8.98CAD 898Jul 13, 2026
Franklin Milan Berger
Director of Issuer
Buy1CAD 8.49CAD 8Jul 13, 2026
Franklin Milan Berger
Director of Issuer
Buy1,000CAD 9.07CAD 9,070Jul 13, 2026
Franklin Milan Berger
Director of Issuer
Buy100CAD 9.01CAD 901Jul 13, 2026
Franklin Milan Berger
Director of Issuer
Buy203CAD 8.97CAD 1,821Jul 13, 2026
Franklin Milan Berger
Director of Issuer
Buy1,325CAD 8.92CAD 11,819Jul 13, 2026
Franklin Milan Berger
Director of Issuer
Buy327CAD 8.88CAD 2,904Jul 13, 2026
Franklin Milan Berger
Director of Issuer
Buy3CAD 8.87CAD 27Jul 13, 2026
Franklin Milan Berger
Director of Issuer
Buy164CAD 8.94CAD 1,466Jul 13, 2026
Franklin Milan Berger
Director of Issuer
Buy200CAD 9.00CAD 1,800Jul 13, 2026
Franklin Milan Berger
Director of Issuer
Placement24,750CAD 13.71CAD 339KFeb 9, 2026

Big stakes

StakeStakeSharesDateFiling
Qiming U.S. Healthcare Fund III, L.P.8.30%1.73MMar 31, 2026Schedule 13G
Brian Matthew Bloom7.35%1.13MFeb 6, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Adam MostafaDirector | Chair, Audit Committee · Since at least Jun 18, 2025
Antoinette PaoneChief Development Officer and Head of Regulatory Affairs · Since at least Jan 29, 2026
Brian BloomDirector · Since at least Jun 18, 2025
Caitlin LowieVice President, Investor Relations & Communications · Since at least Oct 27, 2026
Frank GleesonCo-founder, Chief Executive Officer, Board Director · Since at least Oct 5, 2026
Franklin M. BergerDirector · Since at least Feb 9, 2026
Geoff MacKayChair, BOD | Chair, Compensation Committee · Since at least Jun 18, 2025
Iris Loew-FriedrichDirector · Since at least Jun 18, 2025
Liz WilliamsCFO · Since at least Mar 27, 2026
Mark NawackiDirector · Since at least Nov 14, 2025
All 13 people
PersonSeat
Selwyn HoDirector · Since at least Jun 18, 2025
Stephanie BrownDirector | Chair, Nominations and Governance Committee · Since at least Jun 18, 2025
Wildon Farwellchief medical officer · Aug 13, 2025 – Nov 4, 2026 · Past

Open People

Log in to ask 6ix AI your own questions about Satellos Bioscience Inc.